CA2516931C - Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders - Google Patents

Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders Download PDF

Info

Publication number
CA2516931C
CA2516931C CA2516931A CA2516931A CA2516931C CA 2516931 C CA2516931 C CA 2516931C CA 2516931 A CA2516931 A CA 2516931A CA 2516931 A CA2516931 A CA 2516931A CA 2516931 C CA2516931 C CA 2516931C
Authority
CA
Canada
Prior art keywords
amino
carbonyl
carboxamide
cndot
phenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2516931A
Other languages
English (en)
French (fr)
Other versions
CA2516931A1 (en
Inventor
Jacques Dumas
Stephen Boyer
Sharad Verma
Lila Adnane
Yuanwei Chen
Wendy Lee
Barton Phillips
Roger A. Smith
William J. Scott
Jennifer Burke
Jianqing Chen
Zhi Chen
Jianmei Fan
Karl Miranda
Brian Raudenbush
Aniko Redman
Jianxing Shao
Ning Su
Gan Wang
Lin Yi
Qingming Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Original Assignee
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare LLC filed Critical Bayer Healthcare LLC
Publication of CA2516931A1 publication Critical patent/CA2516931A1/en
Application granted granted Critical
Publication of CA2516931C publication Critical patent/CA2516931C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
CA2516931A 2003-02-28 2004-03-01 Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders Expired - Fee Related CA2516931C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45034803P 2003-02-28 2003-02-28
US60/450,348 2003-02-28
PCT/US2004/006287 WO2004078748A2 (en) 2003-02-28 2004-03-01 Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders

Publications (2)

Publication Number Publication Date
CA2516931A1 CA2516931A1 (en) 2004-09-16
CA2516931C true CA2516931C (en) 2014-09-09

Family

ID=32962496

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2516931A Expired - Fee Related CA2516931C (en) 2003-02-28 2004-03-01 Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders

Country Status (5)

Country Link
EP (1) EP1608639A2 (ja)
JP (1) JP5229853B2 (ja)
CA (1) CA2516931C (ja)
MX (1) MXPA05009104A (ja)
WO (1) WO2004078748A2 (ja)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP2002534468A (ja) 1999-01-13 2002-10-15 バイエル コーポレイション ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
WO2003068228A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
PT1580188E (pt) 2002-02-11 2012-01-25 Bayer Healthcare Llc Aril-ureias como inibidores de cinases
DE602004011340T2 (de) 2003-05-20 2008-11-06 Bayer Healthcare Llc Diaryl-harnstoffe mit kinasehemmender wirkung
ME00294B (me) 2003-07-23 2011-05-10 Bayer Pharmaceuticals Corp Fluoro supstituisana omega-karaboksiaril difenil urea za liječenje i prevenciju bolesti i stanja bolesti
US7071182B2 (en) * 2003-12-23 2006-07-04 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
EP1718637A2 (en) * 2004-02-26 2006-11-08 MERCK PATENT GmbH Benzimidazolyl derivatives as kinase inhibitors
JP2008515884A (ja) * 2004-10-08 2008-05-15 アストラゼネカ・アクチエボラーグ 新規なヒドロキシメチルベンゾチアゾールアミド
US9737488B2 (en) 2005-03-07 2017-08-22 Bayer Healthcare Llc Pharmaceutical composition for the treatment of cancer
BRPI0502016B8 (pt) * 2005-06-03 2021-05-25 Univ Federal Do Rio De Janeiro Ufrj composto ureídicos, composições farmacêuticas contendo os mesmos e seu uso no tratamento de doenças inflamatórias
EA015198B1 (ru) * 2006-03-23 2011-06-30 Биота Юроп Лимитед Антибактериальные агенты
DE102006029795A1 (de) * 2006-06-27 2008-01-03 Schebo Biotech Ag Neue Harnstoff-Derivate und deren Verwendungen
ES2371723T3 (es) 2006-12-20 2012-01-09 Bayer Healthcare, Llc 4-{4-[({3-terc-butil-1-[3-(hidroximetil)fenil]-1h-pirazol-5-il}carbamoil)amino]-3-clorofenoxi}-n-metilpiridina-2-carboxamida como un inhibidor de vegfr cinasa para el tratamiento contra el cáncer.
US20110281909A1 (en) 2007-08-15 2011-11-17 Glaxo Group Limited Substituted quinoline derivatives as h1 receptor antagonists
CN102295600A (zh) * 2011-09-08 2011-12-28 天津大学 5-氨基-8-羟基喹啉的制备方法
WO2013138753A1 (en) 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
CN103508961B (zh) 2012-06-26 2015-07-22 中美冠科生物技术（太仓）有限公司 抗肿瘤药物
CN104250226B (zh) * 2013-06-27 2019-04-26 常州方楠医药技术有限公司 一种制备瑞格菲尼中间体的方法
WO2017047803A1 (ja) * 2015-09-17 2017-03-23 三栄源エフ・エフ・アイ株式会社 増粘多糖類含有製剤の製造方法
JP2019528279A (ja) * 2016-08-17 2019-10-10 アイカーン スクール オブ メディシン アット マウント サイナイ キナーゼ阻害物質化合物、組成物、及びがんの治療方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001930A (en) 1997-03-13 1999-12-14 Acushnet Company Golf ball forming compositions comprising polyamide blended with sulfonated or phosphonated polymers
IL135176A0 (en) * 1997-11-10 2001-05-20 Bristol Myers Squibb Co Benzothiazole derivatives and pharmaceutical compositions containing the same
TR200002616T2 (tr) 1997-12-22 2000-11-21 Bayer Corporation Simetrik ve simetrik olmayan sübstitüe edilmiş difenil üreler kullanılarak raf kinazın inhibe edilmesi
ATE529109T1 (de) 1997-12-22 2011-11-15 Bayer Healthcare Llc Hemmung der p38 kinase aktivität durch substituierte heterocyclische harnstoffe
CA2315713C (en) 1997-12-22 2011-02-01 Bayer Corporation Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas
DE69831013T2 (de) * 1997-12-22 2006-04-20 Bayer Pharmaceuticals Corp., West Haven Inhibierung der raf-kinase durch substituierte heterocyclische harnstoffverbindungen
PT1043995E (pt) 1997-12-22 2007-01-31 Bayer Pharmaceuticals Corp Inibição da actividade de p38-quinase utilização de ureias heterocíclicas substituídas com arilo ou heteroarilo
ATE297383T1 (de) 1997-12-22 2005-06-15 Bayer Pharmaceuticals Corp Hemmung der p38 kinase unter verwendung von symmetrischen und asymmetrischen diphenylharnstoffen
US20020065296A1 (en) * 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928239B2 (en) * 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
JP2002534468A (ja) * 1999-01-13 2002-10-15 バイエル コーポレイション ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
US7351834B1 (en) * 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6492393B1 (en) * 1999-11-16 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
WO2002085357A1 (en) 2001-04-18 2002-10-31 Euro-Celtique, S.A. Nociceptin analogs
JP4366936B2 (ja) * 2001-04-20 2009-11-18 バイエル コーポレイション キノリル、イソキノリルまたはピリジル尿素を使用するｒａｆキナーゼの阻害
WO2003068228A1 (en) * 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
WO2004078128A2 (en) * 2003-02-28 2004-09-16 Bayer Pharmaceuticals Corporation Substituted pyridine derivatives useful in the treatment of cancer and other disorders

Also Published As

Publication number Publication date
EP1608639A2 (en) 2005-12-28
JP5229853B2 (ja) 2013-07-03
JP2006519265A (ja) 2006-08-24
WO2004078748A3 (en) 2004-11-11
MXPA05009104A (es) 2006-05-31
WO2004078748A2 (en) 2004-09-16
CA2516931A1 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
US8076488B2 (en) Bicyclic urea derivatives useful in the treatment of cancer and other disorders
CA2516931C (en) Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
JP4927533B2 (ja) 癌その他の疾患の治療に有用な置換ピリジン誘導体
EP1599466B1 (en) 2-oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatrory disorders
EP1751139B1 (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer
EP1973897B1 (en) Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20220901

MKLA Lapsed

Effective date: 20210301

MKLA Lapsed

Effective date: 20210301